A recent clinical trial has demonstrated that patients with both chronic kidney disease (CKD) and type 2 diabetes (T2D) experience greater improvement in a key biomarker for kidney function when treated with a combination of the drugs finerenone and empagliflozin, as compared to treatment with either drug individually.
The findings come from the CONFIDENCE trial, a study funded by Bayer and registered under ClinicalTrials.gov number NCT05254002. The trial focused on the urinary albumin-to-creatinine ratio (UACR), which is an important indicator of kidney damage. Elevated UACR levels are common in individuals with both CKD and T2D and are associated with faster disease progression and higher cardiovascular risk.
Participants in the trial received initial therapy consisting of either finerenone alone, empagliflozin alone, or a combination of both drugs. The results showed that the combination therapy was more effective in reducing the UACR, suggesting a potential synergistic effect between the two medications.
Finerenone is a non-steroidal mineralocorticoid receptor antagonist that has been shown to reduce inflammation and fibrosis in the kidneys. Empagliflozin, on the other hand, is a sodium-glucose co-transporter-2 (SGLT2) inhibitor used to lower blood sugar levels, with additional cardiovascular and renal benefits.
These findings are significant because they suggest a new therapeutic strategy for managing patients who face the dual burden of CKD and T2D. Further research may be needed to explore long-term outcomes and confirm these benefits across broader patient populations. Nonetheless, the data present a promising advancement in the treatment of complex comorbid conditions.
Source: https:// – Courtesy of the original publisher.
